I don't think anything is stopping them from announcing interim results from 008. I can't see any information in the statistical methods portion of the study design that would make me think they would be penalised if they were to announce interim results.
What is also intriguing to me is that in the statistical methods section of the study design it also mentions "This study is descriptive in nature, and no formal hypothesis testing will be performed."
Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-71
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |